AusperBio is a clinical-stage biopharmaceutical company operating in the USA and China, focused on developing transformative oligonucleotide therapies, particularly targeting a functional cure for chronic hepatitis B. Utilizing its proprietary Med-Oligo™ ASO platform, the company enhances antisense oligonucleotide therapeutics, aiming to address a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
Leadership & Board
Current Number of Employees10
Current LinkedIn Followers989
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$186M
Total Amount Raised$186M
Total Funding Rounds3
Total Funding Rounds3
Latest Funding Amount$63M
Latest Funding Amount$63M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
AusperBio had 10 employees as of August 3, 2026. The number of employees increased by 0 (0.00%) week-over-week.
10Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
AusperBio had 989 followers as of August 3, 2026. The number of followers increased by 1 (0.10%) week-over-week.
989Latest Followers Count
1(0.10%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.